Inventor · disambiguated record
Richard Louis Remmele, Jr.
Also filed as: REMMELE JR RICHARD L · REMMELE JR RICHARD LOUIS · REMMELE RICHARD L · REMMELE RICHARD LOUIS
11 granted patents·14 pending applications·203 citations·filing 2002–2021
91Inventor score
Top patents by PatentIndex Score
25 records- 0198US7648702B2Stable aqueous formulation of a soluble TNF receptor and arginineIMMUNEX CORP·Filed 2007·Granted Jan 19, 2010·123 cites·26 claims
- 0292US8119604B2Polypeptide formulationGOMBOTZ WAYNE R·Filed 2009·Granted Feb 21, 2012·20 cites·20 claims
- 0391US7544784B2Increased recovery of active proteinsIMMUNEX CORP·Filed 2006·Granted Jun 9, 2009·14 cites·35 claims
- 0490US9518111B2Compositions comprising a p75 tumor necrosis factor receptor/Ig fusion proteinIMMUNEX CORP·Filed 2014·Granted Dec 13, 2016·8 cites·23 claims
- 0590US7157557B2Increased recovery of active proteinsIMMUNEX CORP·Filed 2002·Granted Jan 2, 2007·25 cites·49 claims
- 0685US8828947B2Polypeptide formulationGOMBOTZ WAYNE RICHARD·Filed 2012·Granted Sep 9, 2014·7 cites·23 claims
- 0779US11607451B2Self-buffering antibody formulationsAMGEN INC·Filed 2013·Granted Mar 21, 2023·1 cites·96 claims
- 0878US11104714B2Compositions comprising a P75 tumor necrosis factor receptor/Ig fusion proteinIMMUNEX CORP·Filed 2019·Granted Aug 31, 2021·0 cites·10 claims
- 0978US2022025016A1Compositions comprising a p75 tumor necrosis factor receptor/ig fusion proteinIMMUNEX CORP·Filed 2021·Application pending·0 cites
- 1073US9283260B2Lyophilized therapeutic peptibody formulationsCALLAHAN WILLIAM J·Filed 2007·Granted Mar 15, 2016·5 cites·8 claims
- 1169US2019144523A1Compositions comprising a p75 tumor necrosis factor receptor/ig fusion proteinIMMUNEX CORP·Filed 2019·Application pending·0 cites
- 1263US2017051039A1Compositions comprising a p75 tumor necrosis factor receptor/ig fusion proteinIMMUNEX CORP·Filed 2016·Application pending·0 cites
- 1363US2017368170A1Self-buffering protein formulationsAMGEN INC·Filed 2017·Application pending·0 cites
- 1460US2016367666A1Self-buffering protein formulationsAMGEN INC·Filed 2016·Application pending·0 cites
- 1559US2016367665A1Self-buffering protein formulationsAMGEN INC·Filed 2016·Application pending·0 cites
- 1659US2016319011A1Self-buffering protein formulationsAMGEN INC·Filed 2016·Application pending·0 cites
- 1759US2016362486A1Self-buffering protein formulationsAMGEN INC·Filed 2016·Application pending·0 cites
- 1859US2016339102A1Self-buffering protein formulationsAMGEN INC·Filed 2016·Application pending·0 cites
- 1959US2016362484A1Self-buffering protein formulationsAMGEN INC·Filed 2016·Application pending·0 cites
- 2059US2016362485A1Self-buffering protein formulationsAMGEN INC·Filed 2016·Application pending·0 cites
- 2157US9920114B2Antibody formulationsAMGEN INC·Filed 2017·Granted Mar 20, 2018·0 cites·14 claims
- 2256US2008311078A1Self-Buffering Protein FormulationsGOKARN YATIN R·Filed 2006·Application pending·0 cites
- 2356US2003180287A1Polypeptide formulationIMMUNEX CORP·Filed 2003·Application pending·0 cites
- 2455US2012028877A1Self-Buffering Protein FormulationsGOKARN YATIN R·Filed 2011·Application pending·0 cites
- 2545US10166189B2Lyophilized therapeutic peptibody formulationsAMGEN INC·Filed 2016·Granted Jan 1, 2019·0 cites·6 claims
Join the waitlist — get patent alerts
Get an alert when Richard Louis Remmele, Jr. files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →